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Abstract
The cancer stem cell (CSC) theory predicts that a small fraction of cancer cells possess unique self-renewal activity and
mediate tumor initiation and propagation. However, the molecular mechanisms involved in CSC regulation remains unclear,
impinging on effective targeting of CSCs in cancer therapy. Here we have investigated the hypothesis that Rac1, a Rho
GTPase implicated in cancer cell proliferation and invasion, is critical for tumor initiation and metastasis of human non-small
cell lung adenocarcinoma (NSCLA). Rac1 knockdown by shRNA suppressed the tumorigenic activities of human NSCLA cell
lines and primary patient NSCLA specimens, including effects on invasion, proliferation, anchorage-independent growth,
sphere formation and lung colonization. Isolated side population (SP) cells representing putative CSCs from human NSCLA
cells contained elevated levels of Rac1-GTP, enhanced in vitro migration, invasion, increased in vivo tumor initiating and
lung colonizing activities in xenografted mice. However, CSC activity was also detected within the non-SP population,
suggesting the importance of therapeutic targeting of all cells within a tumor. Further, pharmacological or shRNA targeting
of Rac1 inhibited the tumorigenic activities of both SP and non-SP NSCLA cells. These studies indicate that Rac1 represents a
useful target in NSCLA, and its blockade may have therapeutic value in suppressing CSC proliferation and metastasis.
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Introduction
Lung cancer remains the leading cause of cancer deaths
worldwide. The disease is broadly classified into two histo-
pathological groups - small cell lung cancer (SCLC) and non-
small cell lung cancer (NSCLC), with the later group representing
,80% of lung cancer cases. Adenocarcinomas occur in about
55% of the NSCLC and 40% of all lung cancers. Despite of
continued development of cancer therapeutics, currently the
overall five year survival rate for lung cancer patients is less than
15%[1]. Often, existing chemotherapy, radiation therapy or
surgery can only partly remove the tumor burden, leaving behind
therapy resistant cancer cells that may regenerate the tumor at the
primary site and/or metastasize to secondary sites to initiate new
tumors.
Recent publications have reported the identification of cancer
initiating or cancer stem cells (CSCs) from blood [2], brain [3],
breast [4], colon [5,6], hepatic [7], pancreatic [8], prostrate [9,10],
as well as lung cancers [11,12,13]. The CSCs are identified either
by unique cell properties such as Hoechst dye exclusion (Hoechst
dye-low side population) or by expression of specific surface
markers such as CD133, ALDH, or CD24/CD44, and they are
frequently associated with chemotherapy and radiation therapy
resistance. CSCs are defined by their stem cell like self-renewal
capabilities, their ability to differentiate into cell types that
constitute the bulk of the tumor, and to initiate tumors at a
significantly reduced dosage in mouse xenograft studies [7,14].
NSCLC initiating cells have been isolated from human lung
cancer cell lines based on increased Hoechst 33342 dye efflux
activity [12]. The Hoechst dye low side population (SP) cells are
enriched for tumor initiating activity compared to non-side
population (NSP) cells and express elevated ABCG2 and other
multi-drug resistance transporters that may mediate therapeutic
resistance.
The advancement of the cancer stem cell theory has led to the
proposal that targeting CSC’s can lead to eradication of the
residual therapy resistant tumor cells in patients. Recently Gupta
et al suggested that inducing differentiation of CSC by using
salinomycin, a selective potassium ionophore can block mammary
CSC activity and metastasis [15]. However, several recent reports
have shown that CSCs and non-CSCs can be plastic and inter-
convertible in nature [16–17]. For example, JARID1 negative cells
were shown to represent a transient slow cycling non-CSC
population that can give rise to fast cycling JARID1 positive CSCs
in melanoma (13). There is evidence that non-CSCs can convert to
CSCs through interaction with extracellular matrix and other
environmental cues (14). This raises the possibility that approaches
solely targeting CSCs are not sufficient for cancer therapy, because
the remaining non-CSCs may be reprogrammed to CSCs to
reinitiate tumorigenesis.
Rac1 is an intracellular molecular switch that transduces signals
in a variety of oncogenic pathways. It is frequently found to be
elevated in expression and/or activity in a variety of tumor cells
and regulate important cellular processes relevant to cancer cell
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cytoskeleton remodeling and is essential for cell directional
migration and adhesion. Rac1 activity can influence cell cycle
progression and survival, and it was shown to be required in K-ras
mediated lung tumor growth in a murine spontaneous lung cancer
model [18]. However, whether Rac1 contributes to human
NSCLA tumor growth and/or metastasis, particularly if Rac1
plays a role in regulating CSCs, requires further investigation. In
the current work we show that Rac1 is critically involved in
NSCLA cell migration, invasion and lung metastasis of SP cells,
therefore serving as a useful therapeutic target by inhibiting tumor
initiation and metastasis of the CSC population of NSCLA.
Materials and Methods
Cell culture
A549, H23, H1299 and H441 cells were cultured according to
the guidelines from ATCC. Human bronchial epithelial cells
(HBEC) were generous gift from Dr. Jeffery Whitsett (Cincinnati
Children’s Hospital Medical Center). Primary patient lung
adenocarcinoma samples were obtained with written consent
from patients under an approved Institution Review Board
protocol by University of Cincinnati Scientific Review Committee
(IRB# 01-09-27-07), and were used in the experiments according
to Cincinnati Children’s Hospital Medical Center Scientific
Review Committee (IRB # 07-06-57) that the identity of the
patients remains anonymous. Tumors were minced and resus-
pended in DMEM containing 0.5 mg/ml Liberase (Roche) and
1% penicillin and streptomycin. After 45 minute incubation, slurry
of cells was passed through 100 micron filter and total cells were
washed, plated in 10% fetal bovine serum containing growth
media. Epithelial cancer cells were enriched by growing cells in
sphere culture conditions.
A549, H23, H1299, H441, HBEC or primary adenocarcinoma
cells were infected with lentivirus expressing YFP tagged
scrambled shRNA (scr) or Rac1 shRNA1 or Rac1 shRNA2
described previously [19]. Scrambled shRNA construct was
generous gift from Dr. Lee Grimes (Cincinnati Children’s Hospital
Medical Center) and Rac1 shRNA constructs were generous gift
from Dr. Jim Mulloy (Cincinnati Children’s Hospital Medical
Center). After 72 hours of infection, YFP positive cells were sorted
using FACS and utilized for different experiments.
For Rac1 mutant rescue experiments, four mismatch point
mutations were made in the shRNA binding sites of Rac1 cDNA
in the MIEG3 vector using site-directed mutagenesis kit
(Stratagene, Agilent technologies) per manufacturer’s directions.
A549 cells were infected with Rac1 mutant expressing retrovirus
and after 72 hours, GFP positive cells were sorted using FACS.
The cells were subsequently infected with lentivirus expressing scr
shRNA or Rac1 shRNA. After 72 hours, GFP
+ YFP
+ cells were
used to perform several functional assays.
Cell proliferation assays
Cells were plated (2000 cells/well) on 96 well plate in triplicates.
Number of live cells on each day was determined by non-
radioactive MTS proliferation assay (Promega).
For BrdU incorporation assay, BrdU (10 mg/ml) was added to
cells at 60% confluency for 2 hours at 37uC. Cells were collected,
fixed, stained and FACS analysis was performed as described
previously [20]. To detect BrdU positive cells in CD133
+ and
CD133
2 populations, cells were stained with CD133/2-APC
antibody (Miltenyi Biotechnologies Inc.) after BrdU staining. The
BrdU positive cells were gated from both CD133
+ and CD133
2
cells.
Soft agar colony formation assay
Cells were seeded (10,000 cells/well) in 0.3% low melting point
agarose made in growth media containing 10% fetal bovine serum
and layered on top of 0.6% agarose in growth media. Number of
colonies formed after either 2 weeks (A549, H1299) or 3 weeks
(H441, H23) was counted under light microscope.
Sphere formation assay
Cells (10,000 cells/ml) were plated in suspension culture
conditions in serum-free sphere media (DMEM:F12 containing
0.4% BSA, 10 mg/ml insulin, 10 ng/ml EGF, 10 ng/ml FGF) on
6-well plates pre-coated with 1% agarose to prevent cell
attachment. Media was replaced every 2–3 days and number of
spheres formed in 2 weeks was counted under light microscope.
Adhesion assay
Plates were coated with 50 mg/ml fibronectin overnight at 4uC
and blocked with 2% BSA for 2 hrs at 37uC. After blocking, Cells
were plated (10,000 cells/well) and incubated at 37uC for 60
minutes. Non-adherent cells were aspirated and plates were
washed three times with PBS. Numbers of cells attached to the
wells after washes were determined by using non-radioactive
proliferation MTS assay.
Migration and invasion assays
For trans-well migration assay, 50,000 cells were added to upper
chamber in serum free media and migration at 37uC towards 10%
FBS containing growth media was determined either after
24 hours (A549, H1299, H23) or 48 hrs (H441). Cells migrated
through the membrane were fixed, stained with Giemsa stain
(Sigma) and counted under light microscope.
For invasion assay, lower chambers of matrigel coated invasion
plates were coated with 10 mg/ml fibronectin overnight at 4uC
and cells invading through matrigel were fixed and stained either
after 48 hours (A549 cells) or 72 hours (H441 cells) similar to
migration assay.
Immuno-staining
Cells were plated on fibronectin coated slides and after 18–
20 hours cells were fixed using 3.7% Formaldehyde. Cells were
stained for actin cytoskeleton (Rhodamine-Phalloidin, Invitrogen),
nuclei (DAPI, Invitrogen) using standard immuno-staining meth-
ods described previously [21]. Alternatively cells were stained with
either phospho-FAK (Focal Adhesion Kinase, Millipore) or
vinculin (Sigma) or phospho-paxillin (Cell signaling Technologies).
Side-population, CD133 cell staining and isolation
Cells are trypsinized and washed with PBS. Cells are stained
with Hoechst 33342 staining buffer as described previously at a
final concentration of 5 mg/ml Hoechst 33342 [22] for side
population (SP), or with anti-CD133 antibody for CD133 positive
cells. The cells were analyzed or sorted for SP/CD133
+ cells by
flowcytometry.
To obtain Rac1 knockdown in SP or CD133
+ cells, cells were
infected with lentivirus expressing YFP tagged scr or Rac1 shRNA
and after 72 hours cells were stained for side population or
CD133. YFP positive SP or non-SP cells were sorted for either
Western analysis or functional assays.
Rac1-GTP pull-down assay
To perform Rac1 pull down assays, cells were lysed by adding
lysis buffer containing 20 mM Tris HCl pH 7.6, 100 mM NaCl,
10 mM MgCl, 1% Triton X-100, 0.2% SDS, protease and
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containing equal amounts of protein were incubated with
glutathione beads conjugated to GST-PAK1 containing active
Rac1 interacting domain and processed further as described
previously [23].
Lung colonization assay
Use of mice as xenograft hosts was approved by the IACUC
committee at Cincinnati Children’s Hospital Medical Center
(Protocol# 8D06052). Specified number of cells were suspended
in PBS and injected intravenously into immune compromised
NOD/SCID/cc -/- (NSG) mice by tail vein injection. At the end
of the study, lungs were fixed in Bouin’s solution to count number
of tumors.
Subcutaneous xenograft assay
Specified number of cells are suspended in 200 mlo f
PBS:matrigel mix (1:1 volume) and injected subcutaneously into
the flanks of immune compromised NOD/SCID/c-/- (NSG)
mice. After 3–4 weeks of injection tumor size was measured weekly
using calipers and the tumor volume was determined by using
formula 0.52XLXW
2 cm3.
Tumor cell homing assay
Cells expressing YFP were injected intravenously into NSG mice.
After 24 hours, lungs were isolated after perfusion with PBS. Total
lung cells were isolated by Liberase digestion and total cell count
was determined by Hemavet cell counter. Percentage of YFP
positive cells was determined by flow-cytometric analysis of total
lung cells. Homing index was determined by calculating percentage
YFP positive cells homed to lung normalized to control cells.
Results
Rac1 targeting impairs proliferation and colony
formation of human NSCLA cells
To investigate the role of Rac1 GTPase in NSCLA cell growth,
A549, H441, H1299, and H23 cells were infected with lentivirus
encoding scr or Rac1 shRNA (shRNA1, 2). Western blot analysis
revealed efficient knockdown of Rac1 protein with both shRNA
constructs (50% and 90% respectively compared to scr) in A549
cells (Fig. 1A). Rac1shRNA1 expression partially reduced the
proliferation of the lung cancer cells while Rac1shRNA2 more
potently inhibited cell growth (Fig. 1B) and caused a significant
decrease of number of colonies grown in soft agar colony
formation assay (Fig. 1C). Further, cell cycle analysis performed
by BrdU staining and FACS analysis revealed a decrease in S-
phase and a corresponding increase in G0/G1 phase of the cell
cycle upon Rac1 targeting (Fig. 1D). In H441 cells, Rac1 shRNA2
led to ,75% reduction in Rac1 protein (Fig. S1A), and a relative
minor effect on proliferation (Fig. S1B). In H1299 and H23 cells,
Rac1 knockdown caused a significant reduction in proliferation
(Fig. S1C, S1E) and soft agar colony formation (Fig. S1D, S1F). To
determine if the Rac1 knockdown effects on proliferation and soft
agar growth are specific to Rac1, we performed shRNA-resistant
Rac1 cDNA mutant rescue experiments in the knockdown cells.
Expressing a Rac1 shRNA resistant mutant cDNA could mostly
rescue the proliferation of Rac1 knocked down in A549 cells
without a detectable effect on the scr shRNA treated control cells
(Fig. 1E). Similarly we observed a rescue of soft agar colony
formation by expressing shRNA-resistant Rac1 cDNA mutant
(Fig. 1F). Together, these results indicate that Rac1 is required for
the proliferative potential of NSCLA cells.
Rac1 knockdown results in decreased adhesion,
migration and invasion of NSCLA cells
Consistent with the known role of Rac1 in cytoskeleton
regulation, Rac1 knockdown in both A549 and H441 cells
resulted in altered actin cytoskeleton organization (data not
shown). Suppression of Rac1 in A549 cells caused decreased focal
adhesion complex formation, with control cells exhibiting robust
focal adhesion complexes visualized by immunostaining for the
focal adhesion proteins p-FAK, vinculin, and p-paxillin whereas
the Rac1shRNA2 infected cells demonstrated reduced focal
adhesion complex formation (Fig. 2A). We also observed
decreased p-FAK, p-paxillin and p-MLC in Rac1 knockdown
cells compared to control cells by Western blot analysis (Fig. S2A).
Consistent with the decreased adhesion complexes in Rac1shRNA
infected cells, adhesion to fibronectin was reduced in these cells
compared to control cells (Fig. 2B). Similar to the effect on
proliferation, Rac1 partial knockdown in H441 cells resulted in a
relatively minor effect on adhesion to fibronectin compared to
A549 cells (Fig. S2B). In addition, Rac1 knockdown in both A549
and H441 cells resulted in decreased trans-well migration and
invasion activities compared to control cells (Figs. 2C, 2D, & Fig.
S2C, Fig. S2D). Similarly, Rac1 knockdown in H1299 or H23
cells drastically decreased migration compared to control cells (Fig.
S2E, Fig. S2F). Expressing a shRNA-resistant Rac1 cDNA mutant
was able to completely rescue the migration phenotype of Rac1
knockdown in A549 cells (Fig. 2E). These data demonstrate the
importance of Rac1 in NSCLA cancer cell adhesion, migration
and invasion.
Rac1 knockdown prevents lung colonization of NSCLA
cells in mice
Next, we examined the effect of Rac1 knockdown on
tumorigenesis and metastatic behavior of lung adenocarcinoma
cells. Rac1 knockdown or control cells were injected intravenously
into immuno-deficient NSG mice in a lung colonization model.
Both A549 (Fig. 3A) and H441 cells (Fig. S3A) expressing Scr
(500,000 cells/mouse) caused tumor formation in the lungs while
Rac1 knockdown cells (500,000 cells/mouse) failed to form tumors
in the lungs 8 weeks post-injection. As expected, Rac1shRNA1
infected cells that showeda partialRac1 protein knockdownformed
reduced number of tumors. To determine if the effect on lung
colonization is related to a homing defect of the Rac1 knockdown
cells in the lung, we tested the ability of the tumor cells to home to
the lung tissue 48 hours after tail vein injection. Flow cytometry
analysis revealed that the YFP
+ Rac1 knockdown cells displayed
significantly decreased lung homing activity compared to the YFP
+
Scr cells (Fig. 3B). In addition, subcutaneous xenograft of the tumor
cells (500,000 cells/mouse) in NSG mice established that Rac1
knockdown cells had delayed tumor development and reduced
tumor volume compared with the control cells (Fig. 3C). Interest-
ingly, sphere formation of H441 cells, which correlates with tumor
initiating potential, was also compromised upon Rac1 knockdown
(Fig. S3B) whereas no effect was observed by Rac1 knockdown on
sphere forming activity of the non-transforming HBEC control cells
(Fig. S3C). Thus, it is likely that Rac1 knockdown effects tumor cell
lung colonization, growth due to a combined effect on cancer cell
homing and proliferation in the lung.
Side population cells contain elevated Rac1-GTP and
increased migration, invasion, and lung colonization
activities
The cancer stem cell theory suggests that a fraction of the
cancer cell population is enriched for tumor initiating capability,
Rac1 Targeting in Lung Cancer Stem Cells
PLoS ONE | www.plosone.org 3 February 2011 | Volume 6 | Issue 2 | e16951thus requiring preferential targeting to achieve therapeutic
benefits. Side population is one of the stem cell markers that has
been used to isolate lung cancer stem cells [12]. We isolated SP
cells by flow cytometry from A549 cells (Fig. 4A) and confirmed by
RT-PCR that they express increased ABCG2 transporter (Fig.
S4A). Interestingly, SP cells contained increased Rac1 activity
(Fig. 4B) and displayed increased migration compared to non-SP
cells or parental cells (Fig. 4C). Inhibition of the Rac1 activity by
Figure 1. Knocking down Rac1 expression effectively inhibits human non-small cell lung cancer cell proliferation. (A) Cell lysates
collected from either scrambled shRNA (Scr) or Rac1 shRNA (shRNA1, shRNA2) A549 cells were subjected to Rac1 western blot analysis. GAPDH was
used as loading control. (B) Infected cells were sorted and plated on 96-well plate and proliferation assay was performed using MTS reagent. Assay
was performed in triplicates and above is one representative of three independent experiments. (C) Infected cells were sorted, plated for soft agar
colony assay and colonies per field were counted after 2 weeks. Assay was performed in triplicates and above is one representative of three
independent experiments. (D) Infected cells were sorted and incubated with BrdU in log phase of cell growth. Cells are trypisinized, stained with BrdU
antibody, 7AAD and cell cycle analysis was performed using flowcytometry. Assay was performed in triplicates and above is one representative of
four independent experiments. Error bars represents SD. (E) Control cells or cells expressing shRNA resistant Rac1 mutant were infected with scr or
Rac1 shRNAs, sorted and plated on 96-well plate. Proliferation assay was performed using MTS reagent. Assay was performed in triplicates and above
is one representative of two independent experiments. (F) Infected cells were sorted, plated for soft agar colony assay and colonies were counted
after 10 days. Assay was performed in triplicates and above is one representative of two independent experiments.
doi:10.1371/journal.pone.0016951.g001
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plated on fibronectin coated slides and stained with either p-FAK (top panel) or vinculin (middle panel) or p-Paxillin (lower panel) and DAPI. Images
were collected using fluorescent microscope at 40X magnification. Images above are representative of several images obtained from two
independent experiments. (B) A549 sorted cells were plated on fibronectin coated 96-well plate for in vitro adhesion assay and cells attached to plate
after 1 hour was determined using MTS reagent. Adhesion assay was performed with five replicates and the data is representative of three
independent experiments. (C) Sorted cells were plated on trans-well migration plates and migration of cells toward 10% FBS was measured
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decreased migration and invasion of SP cells (Fig. S4B, S4C),
suggesting elevated Rac1-GTP in the SP cells contributes to these
tumor cell behaviors. Furthermore, the SP cells showed increased
lung colonization capability in vivo compared to non-SP or parental
cells (Fig. 4D). Interestingly, despite distinct tumor initiating
activities in vivo, SP and non-SP cells proliferated at a similar rate
as the parental cells in vitro (Fig. S4D). However, SP cells displayed
increased colony formation activity when growing in soft agar
compared to non-SP and parental cells (Fig. S4E). The residual
tumorigenic activity exhibited by the non-SP cells was not due to
impurity of these cells, because parallel FACS analysis found over
99.9% enrichment for non-SP cells from the Hoechst 33342 dye
sorting (data not shown). Therefore it is likely that a plasticity of
the non-SP cells allows them to give rise to cancer initiating cells
resulting in the observed residual tumorigenicity.
SP cells were also detected in H441 cells at a lower percentage
than A549 cells (Fig. S4F; 0.5–2% vs. 4–10%). Similar to A549 SP
cells, H441 SP cells displayed increased lung colonization in
immune compromised mice compared to non-SP cells (Fig. S4G),
and formed more colonies in soft agar compared with non-SP and
parental cells (Fig. S4H).
These results lead us to conclude that SP cells from NSCLA
represent a subpopulation in the bulk tumor cells that contain
elevated Rac1 activity, increased migration, invasion, anchorage-
independent growth activities, and are enriched for cells that are
capable of colonizing lung. They also suggest that non-SP cells
could remain tumorigenic, albeit with reduced CSC activity, to
give rise to tumors.
Rac1 knockdown suppresses adhesion, migration, and
invasion of both SP and non-SP cells
To further examine the effect of Rac1 knockdown on SP cells,
A549 cells were infected with lentivirus either containing scr or
Rac1 shRNA, and SP and non-SP cells were isolated by flow
cytometry. Western blot analysis confirmed the effectiveness of
Figure 3. Knocking down Rac1 expression suppresses lung cancer cell homing and tumor growth in the lung of recipient mice. (A)
5610
5 A549 cells were injected into tail vein of NSG mice (n=6 per condition) and lungs were dissected after 8 weeks. Lung were stained with Bouins
solution and destained in 70% ethanol. Quantification of lung colonization data was shown in the right panel. Error bar represents SE. Depicted is a
representative of two independent experiments. (B) Tumor cell homing assay was performed as described in methods (n=6 per condition in each
experiment). Homing index was measured as percentage of YFP positive cells detected in lung, normalized to control. Depicted is a representative of
three independent experiments. (C) 5610
5 scr or Rac1 shRNA infected cells were injected subcutaneous into flanks of NOD/SCID mice and tumor
volume was measured weekly for 7 weeks. Error bar represents SE.
doi:10.1371/journal.pone.0016951.g003
overnight. Assay was performed in replicates and above data was representative of three independent experiments. (D) Sorted A549 cells were plated
on matrigel coated invasion plates and migration of cells toward 10% FBS and 10 mg/ml fibronectin was measured after 48 hours. Assay was
performed in triplicates and the above is a representative of three independent experiments. Error bars represents SD. (E) Control or cells expressing
Rac1shRNA resistant mutant were infected with Rac1 shRNA and sorted. Cells were plated on trans-well migration plates and migration of cells
toward 10% FBS was measured overnight. Assay was performed in triplicates and above data was representative of two independent experiments.
doi:10.1371/journal.pone.0016951.g002
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with our earlier data on parental cells, Rac1 knockdown altered
the cytoskeletal organization of both SP and non-SP cells (Fig.
S5B), and reduced focal adhesion complexes as visualized by p-
FAK immunostaining of both SP and non-SP cells (Fig. 5A).
Consistently, the adhesion activity of both SP and non-SP cells to
fibronectin was also decreased (Fig. 5B). Further, Rac1 knockdown
decreased migration and invasion of both SP and non-SP cells
(Fig. 5C, 5D). Thus, Rac1 targeting can suppress migration and
invasion of both SP and non-SP cancer cells.
Figure 4. Side population cells possess elevated Rac1 activity, increased migration, invasion and proliferative activities, and
enriched tumor initiating activity in mouse lung. (A) A549 cells were stained with Hoechst 33342 dye and analyzed by flowcytometry for side
population (left panel). Cells were treated with 10 mM Fumitremorgen for inhibitor control (right panel). Depicted is a representative of several SP
analyses. (B) Cell lysates collected from sorted SP and non-SP cells were subjected to GST-PAK pull down assay and processed for Rac1 western blot
analysis to determine the Rac1 activity. Total Rac1 blot was used as a control. Depicted is a representative of three independent Rac1 activity pull-
down assays. (C) Sorted A549 cells were plated for trans-well migration assay and cells migrated overnight towards 10% FBS were stained and
counted. Above is a representative of three independent experiments and error bars represents SD. (D) 5610
4 sorted SP and non-SP cells were
injected into tail vein of NSG mice (n=4 per condition). Lungs were dissected out at the end of 12 weeks. Right panel shows quantification of lung
colonization data. Error bar represents SE. Above is a representative of three independent experiments.
doi:10.1371/journal.pone.0016951.g004
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colonization of both SP and non-SP cells
To examine whether the observed inhibition of proliferation of
the overall cancer cell population by Rac1 knockdown is due to a
specific effect on CSCs, we next tested the growth properties of
isolated SP and non-SP cells before and after transduction of
Rac1-specific shRNA. The proliferation of SP and NSP cells in
vitro appeared similar under standard tissue culture conditions, and
Rac1 knockdown blocked in vitro proliferation of both SP and non-
SP cells to the similar extent (Fig. 6A). BrdU labeling showed that
both SP and non-SP cells were inhibited in S-phase transition with
a corresponding increase in G0/G1 phase of cell cycle after Rac1
knockdown (Fig. 6B). While scrambled RNA did not affect the
increased colony formation activity of SP cells in a soft agar assay
compared with non-SP cells in either reduced serum or normal
serum conditions (Fig. 6C; data not shown), Rac1 shRNA was able
to significantly reduce colony formation of both SP and non-SP
A549 cells. In tail-vein injected NSG mice, the lung colonization of
Rac1 shRNA SP cells was drastically decreased compared to scr
cells and the corresponding non-SP cells showed no tumor
colonization activity (Fig. 6D). These results provide strong
evidence that Rac1 targeting is effective in inhibiting proliferation
and metastasis of both SP and non-SP cells. To test if the Rac1
knockdown effects on proliferation are applicable to cancer stem
cells marked by CD133, a BrdU incorporation assay was
performed in which BrdU positive cells were gated in CD133
+
or CD133
2 population of both scr and Rac1 shRNA treated cells.
We observed a decrease in the BrdU
+ cells in both CD133
+ and
CD133
2 subpopulations upon Rac1 knockdown (Fig. 6E). Thus,
Rac1 is required for proliferation of the CSC population.
Rac1 knockdown decreases migration, invasion, sphere
formation, and metastatic activities of primary human
NSCLA cells
To further examine the relevance of Rac1 targeting on NSCLA
cells, we have determined the functional outcomes of Rac1
Figure 5. Targeting Rac1 effectively suppresses the adhesion, migration and invasion activities of SP cells as well as non-SP cells. (A)
Sorted cells were plated on fibronectin coated slides, fixed and subjected to immunostaining with p-FAK antibody. Cell images were collected at 40X
magnification using Fluorescent microscope. Above depicted are representative of multiple images collected. (B, C, D) A549 sorted cells were either
plated on fibronectin coated 96-well plate for in vitro adhesion assay (B), on trans-well plates for migration assay (C) or matrigel coated invasion plates
for invasion assay (D). All assays were performed in triplicates and error bars represent SD. Depicted are representative of three independent
experiments.
doi:10.1371/journal.pone.0016951.g005
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vivo. (A) Sorted cells were plated in 96-well plate and proliferation assay was performed using MTS reagent. Assay was performed in triplicates and
error bars represents SD. Depicted is a representative of three independent experiments. (B) A549 sorted cells were incubated with BrdU and cell
cycle analysis was performed by BrdU staining and flowcytometric analysis. Assay was performed in triplicates and error bars represent SD. Above is a
representative of two independent experiments. (C) Sorted cell were directly plated for soft agar colony formation assay and the number of colonies
formed were counted after 2–3 weeks. Assay was performed in triplicates and error bars represent SD. Above is a representative of three independent
experiments. (D) 50,000 sorted cells were injected into tail vein of NSG mice and the lungs were isolated for analysis after 12 weeks. Number of lung
tumors was counted under light microscope and error bar represents SE. Results are representative of three independent experiments. (E) Cells were
infected with either scr or Rac1 shRNA and incubated with BrdU. Cells were stained with CD133 antibody during the BrdU staining described in
methods. BrdU positive cells gated from CD133
+ and CD133
2 cells were analyzed by FACS.
doi:10.1371/journal.pone.0016951.g006
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positive (data not shown). Primary human tumor cells were
infected with the lentivirus expressing Scr or Rac1 shRNA and
subsequent Western blot analysis confirmed the effective knock-
down of Rac1 protein expression in the isolated cells (Fig. 7A).
Similar to our observations in NSCLA cell lines, Rac1 knockdown
in the primary patient cells showed a decrease in trans-well
migration and invasion activities (Fig. 7B, 7C). Significantly, the
sphere formation capability was also compromised upon Rac1
knockdown (Fig. 7D, lung adenocarcinoma sample #1) or
NSC23766 treatment in two different lung adenocarcinoma
samples (Fig. S6, lung adenocarcinoma sample #2). Finally,
Rac1 shRNA was effective in suppressing the primary tumor cell
colonization in lung compared to Scr control (Fig. 7E). These
results suggest that Rac1 targeting is beneficial to suppressing
patient NSCLA cancer stem cell activity.
Discussion
In the present work we show that Rac1 is required for adhesion,
migration and lung colonization of NSCLA cells. SP cells isolated
from human adenocarcinoma cell lines have enriched lung
Figure 7. Rac1 targeting inhibits primary non-small cell lung cancer cell migration, invasion, sphere forming and lung colonization
activities. (A) Cells isolated from primary tumor sample were infected with either scr or Rac1 shRNA and sorted cells were subjected to Rac1 western
blot analysis. GAPDH was used as loading control. Above depicted is a representative of multiple western blots. (B, C, D) Primary human
adenocarcinoma cells were plated for either trans-well migration assay (B) or invasion assay (C) or sphere assay (D). For sphere assay, sorted cells were
directed plated in sphere growth media described in methods section. Number of spheres formed after 10 days were counted using light microscope.
All the assays were performed in triplicates and error bar represents SD. Results are representative of three independent experiments. (E) For lung
colonization assay, 5610
5 sorted cells were injected into tail vein of NSG mice (n=4 per condition) and mice were sacked after 6 weeks. Number of
lung tumors was counted under dissecting microscope. Error bar represents SD.
doi:10.1371/journal.pone.0016951.g007
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determined that this is associated with their elevated Rac1 activity
and increased migration and invasion, as well as increased
anchorage-independent growth ability. Importantly, the lung
colonization, migration, and invasion activities of both SP and
non-SP cells can be effectively blocked by either a Rac1 inhibitor
or Rac1 knockdown using shRNA, and the effect may be
applicable to the CD133
+ and CD133
2 cell populations. These
beneficial effects on tumor cell suppression also appear to apply to
primary patient derived NSCLA cells and are irrespective of the
p53 or K-ras mutation status (Table S1). We propose that Rac1
plays a crucial role in regulating CSC tumor initiating, metastatic
activities and thus represents a novel and useful therapeutic target
in NSCLA.
The discovery of a population of self renewing cancer stem
cells in multiple types of cancer including lung cancer has led to
the proposal that CSCs, not non-CSCs in a given tumor, are
responsible for tumor initiation and possibly metastasis
[12,13,24]. Clinical observations of secondary metastasis post-
surgery or -chemotherapy has added to the concept that a
residual population of tumor cells may escape conventional
therapy and give rise to heterogeneous tumors at metastatic sites.
Thus, CSCs are likely the source cells present in the primary
tumors which possess unique proliferative and metastatic
advantages. To date, CSCs are mostly identified by using
various markers. Breast cancer cell lines enriched for CD44
+/
CD24
2 markers express higher levels of pro-invasive genes and
display higher invasive potential [25]. In pancreatic cancer,
CD133
+/CXCR4
+ cells are shown to be responsible for
metastasis [26]. In human liver cancer, CD45
2/CD90
+/
CD44
+ cells form metastatic lesions in the lungs of immune
compromised mice, and blockage of CD44 activity by an
antagonizing antibody is shown to block tumor growth and
metastasis [27]. In line with these observations, SP lung cancer
cells have been shown to possess enriched CSC activity by
forming subcutaneous tumors in xenograft mice at a reduced cell
number [12]. Here, we found that SP cells isolated from NSCLA
cells display increased migration, invasion, homing and lung
colonization activities, in addition to enriched tumorigenic
capability. These observations are consistent with the notion
that CSCs are unique in their metastatic potential as well as
tumor initiation ability.
Conventional chemotherapeutic agents mainly target malignant
cells by either inducing DNA damage or blocking DNA
replication. CSCs may be resistant to the effect of these agents
through their elevated drug resistance or relative quiescence [28].
To apply the CSC theory, several innovative therapeutic strategies
aimed at eradicating CSCs have been developed. To tackle
leukemia CSC, neutralizing antibodies to autocrine signaling
mediators important for CSC growth such as CD123 [29],
antagonist for leukemia CSC localization in the bone marrow
niche such as CXCR4-inhibitor AMD-3100 and CD44 antibodies
[30], and inhibitors of signaling pathways specifically upregulated
in CSCs that are important for the self renewal such as NFk-b
inhibitor parthenolide [31], have been shown to have efficacy in
AML or CML. In solid cancers, IL4 has been shown to be useful
in colorectal cancer stem cell suppression [32,33], BMP4 was
found to induce glioblastoma CSCs to differentiate into non-CSCs
[34], and salinomycin, a selective potassium ionophore, could
target breast cancer stem cell proliferation and induce differenti-
ation [15]. Our current study adds to this list of potential CSC
targeting approaches by presenting evidence that Rac1 inhibition
could be efficacious for suppressing both tumor initiation and
metastasis of NSCLA CSCs.
Effective targeting of CSCs for therapeutic benefit requires
accurate identification of the CSC population. In lung cancer,
CD133
+, ALDH
high, and SP have been used as markers to track
CSC activity, and in vitro anchorage-independent growth, sphere
formation assays and subcutaneous xenograft models have been
employed as readouts for the relative CSC activity [11,12,13].
Although each of these markers may help enrich the CSCs, it is
clear that they do not accurately identify the tumor initiating cells
in human NSCLA tumors, as this population might be quite
complex and could be represented by an overlap of several
different markers. Thus, using SP or CD133 as the sole marker for
CSC identification may not include all CSC activity in a bulk
culture. To this end, it will be interesting to determine whether SP
cells overlap with CD133
+ cells so that a more pure population of
CSCs can be isolated.
The issue of CSC plasticity has been raised recently by several
studies [16,35]. It seems possible that both CSCs and non-CSCs
could be dynamic populations – CSCs able to give rise to non-
CSCs, and non-CSCs may convert to CSCs in given conditions. A
recent review [36] raised an interesting point that the reprogram-
ming from differentiating cancer cells to CSCs, unlike that of
reprogramming of fully differentiated cells into iPS cells, might
occur readily in cancer cells. Recent evidence from Boiko et al [35]
and Roesch et al [16] have shown that non-CSCs can indeed
covert to CSCs under suitable conditions. We have found that
highly purified non-SP cells still retain residue CSC activity in vitro
and in mice, raising the possibility that non-CSCs of NSCLA can
produce CSCs or SP marker is insufficient in identifying CSCs.
This consideration highlights the difficulty of utilizing the CSC
theory to design new strategies against cancer, since it can be
inferred that it will be necessary to effectively target both CSCs
and non-CSCs or multiple marker populations in order to achieve
true therapeutic benefits. Importantly, we show that targeting
Rac1 can effectively block the lung metastatic and tumor initiating
activities of both SP and non-SP NSCLA cells, and such benefits
may apply to the CD133
+/CD133
2 tumor initiating populations.
Future stringent evaluation how Rac1 contributes to various
aspects of CSC activity in multiple marker positive subpopulations
will significantly add to the understanding of Rac1 targeting in
lung tumorigenesis.
Supporting Information
Figure S1 Effects of stable Rac1 suppression on H441,
H1299 and H23 cell proliferation. (A) Cell lysates collected
from either scrambled shRNA (Scr) or Rac1 shRNA (shRNA1)
H441 cells were subjected to Rac1 western blot analysis. GAPDH
was used as loading control. (B) Sorted cells were plated and
incubated with BrdU in log phase of cell growth. Cells are
trypsinized and stained with BrdU antibody, 7AAD to perform cell
cycle analysis. Assay was performed in triplicates and a
representative experiment is shown. Error bars represent SD. (C,
E) H1299 (C) and H23 cells (E) were transduced with lentivirus
expressing either scr shRNA or Rac1 shRNA. 72 hours after the
transduction, cells were plated for a proliferation assay. The
number of cells was determined by MTS measurements at
different time points. Assays were performed in triplicates and
error bars represent SD. (D, F) The cells were plated for soft agar
colony formation assay. Number of colonies formed was counted
under light microscope after 2–3 weeks. Assays were performed in
triplicates and error bar represents SD.
(TIF)
Figure S2 Effect of Rac1 suppression on focal adhesion
complexes, adhesion, migration and invasion. (A) A549
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Cell lysates collected from adherent cells were processed for
p-MLC, p-FAK, p-Paxillin, Rac1 Western blot analysis. GAPDH
was probed as a loading control. Data is representative of three
experiments. (B, C, D) H441 cells expressing either scr or Rac1
shRNAs were sorted and were plated on fibronectin coated plates
for adhesion assay (B), on trans-well migration plate for migration
assay (C) or matrigel coated invasion plates for invasion assay (D).
All assays were performed in triplicates and data are representative
of three independent experiments. Error bars represent SD. (E, F)
H1299 (E) and H23 cells (F) were transduced with either scr
shRNA or Rac1 shRNA and 72 hours later cells were plated for
the trans-well migration assay. Cells migrated overnight were
stained and counted. The assay was performed in triplicates and
error bar represents SD.
(TIF)
Figure S3 Suppression of Rac1 expression in H441 cells
inhibits lung colonization in mice. (A) Lung colonization
assay was performed with scr or Rac1shRNA expressing H441
cells. Number of tumors formed after 12 weeks were counted and
error bar represents SD. Data is representative of three
independent experiments. (B) H441 cells expressing either scr or
Rac1 shRNA were plated for sphere assay as described in
Methods. Number of spheres formed after 10 days were counted
under light microscope. Assay was performed in triplicates and
error bars represent SD. Depicted is a representative of two
independent experiments. (C) HBEC cells expressing either scr or
Rac1 shRNA were plated for the sphere assay. Number of spheres
formed after 10 days were counted under light microscope. The
assay was performed in triplicates and error bars represent SD.
(TIF)
Figure S4 Properties of H441 SP and non-SP cells under
Rac1 suppression. (A) Quantitative RT-PCR for ABCG2
transporter gene was performed using RNA collected from sorted
cells. ABCG2 expression was normalized to GAPDH and the
relative expression was represented as fold-change from control
cells. RT-PCR experiment was performed in triplicates and
depicted is a representative of four independent experiments.
Error bars represents SD. (B) H441 SP cells were plated for
migration assay either in the presence of a vehicle or a Rac
inhibitor, NSC23766 (50 mM). Cells migrated overnight were
quantified as described in Methods. Error bars represent SD and
the depicted is representative of two independent experiments. (C)
H441 SP cells were plated for invasion assays in the presence or
absence of the Rac inhibitor NSC23766 (50 mM). Cells invading
through matrigel were quantified as described in Methods. Error
bars represent SD and the depicted is representative of two
independent experiments. (D) SP, NSP, or non-sorted cells were
plated in 96-well plates and the proliferation was measured by the
MTS assay. Assays were performed in triplicates and error bars
represents SD. Depicted is a representative of three independent
experiments. (E) SP, non-SP, or non-sorted cells were plated for
soft agar colony assay and the colonies were quantified after 2
weeks. Assays were performed in triplicates and error bar
represents SD. Data is representative of two independent
experiments. (F) H441 cells were stained with Heochst dye and
analyzed by flow cytometry. Depicted is representative of three
independent analyses. (G) SP or NSP H441 cells (3610
4) were
sorted and injected into tail vein of NSG mice (n=3 per
condition). Lungs were collected after 10–12 weeks and number
of tumors formed in each lung was counted. Error bar represents
SD. Depicted is representative of three independent experiments.
(H) H441 SP, NSP, or non-sorted cells were plated for soft agar
assay and colonies formed after 21 days were counted. Assays were
performed in triplicates and error bar represents SD. Data is
representative of two independent experiments.
(TIF)
Figure S5 Effect of Rac1 suppression on cell actin
organization. (A) Cell lysates collected from FACS sorted
A549 cells were subjected to Rac1 western blot analysis. GAPDH
was used as loading control. Shown is a representative of three
Western blots. (B) FACS sorted A549 cells were plated onto
fibronectin coated slides and stained for actin cytoskeleton and
nuclei by rhodamine-phalloidin and DAPI, respectively. Shown is
a representative of several images obtained in two independent
experiments.
(TIF)
Figure S6 Effect of Rac1 inhibition on sphere forma-
tion. Cells isolated from primary human lung adenocarcinoma
were plated for sphere assay either in the presence of vehicle or
NSC23766 (50 mM). The number of spheres formed after 10 days
were counted under microscope. Assays were performed in
triplicates and error bars represent SD. Depicted is a represen-
tative of two independent experiments.
(TIF)
Table S1 Summary of Rac1 knockdown data in NSCLA
cell lines.
(TIF)
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